iPierian presented data from its iPSC research programs at the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting. The presentation demonstrated that iPSC lines derived from patients with neurodegenerative diseases retain a ‘memory’ of the gene expression of parental cells. The relatively low variability of iPSC lines derived from individual patients also suggests that a single iPSC line is sufficient to represent a specific patient in disease modeling experiments, making them a useful tool for drug discovery efforts. “iPSCs offer the potential to study certain conditions in disease-specific human model systems for the first time, and we believe our iPS cell technology will ultimately lead to more effective, targeted therapies for patients worldwide,” said Dr. Michael Venuti, President and CSO of iPierian.
Click here to read more.Share this: